Peltatoside Isolated from Annona crassiflora Induces Peripheral Antinociception by Activation of the Cannabinoid System

Abstract

Peltatoside is a natural compound isolated from leaves of Annona crassiflora Mart., a plant widely used in folk medicine. This substance is an analogue of quercetin, a flavonoid extensively studied because of its diverse biological activities, including analgesic effects. Besides, a previous study suggested, by computer structure analyses, a possible quercetin-CB₁ cannabinoid receptor interaction. Thus, the aim of this work was to assess the antinociceptive effect of peltatoside and analyze the cannabinoid system involvement in this action. The mouse paw pressure test was used and hyperalgesia was induced by intraplantar injection of carrageenan (200 µg/paw). All used drugs were administered by intraplantar administration in Swiss male mice (n = 6). Peltatoside (100 µg/paw) elicited a local inhibition of hyperalgesia. The peripheral antinociceptive action of peltatoside was antagonized by the CB₁ cannabinoid antagonist AM251 (160 µg/paw), but not by CB₂ cannabinoid antagonist AM630 (100 µg/paw). In order to assess the role of endocannabinoids in this peripheral antinociceptive effect, we used (i) [5Z,8Z,11Z,14Z]-5,8,11,14-eicosatetraenyl-methyl ester phosphonofluoridic acid, an inhibitor of anandamide amidase; (ii) JZL184, an inhibitor for monoacylglycerol lipase, the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol; and (iii) VDM11, an endocannabinoid reuptake inhibitor. MAFP, JZL184, and VDM11 did not induce antinociception, respectively, at the doses 0.5, 3.8, and 2.5 µg/paw, however, these three drugs were able to potentiate the peripheral antinociceptive effect of peltatoside at an intermediary dose (50 µg/paw). Our results suggest that this natural substance is capable of inducing analgesia through the activation of peripheral CB₁ receptors, involving endocannabinoids in this process.

Key words

Annonaceae - Annona crassiflora - Quercetin - peltatoside - cannabinoid - peripheral antinociception

• References

• 1 Ratter JA, Ribeiro JF, Bridgewater S. The Brazilian Cerrado vegetation and threats to its biodiversity. Ann Bot 1997; 80: 223-230
• 2 Correia MP. Dicionário das plantas úteis e espécies exóticas [Dictionary of useful plants and exotic species]. Rio de Janeiro: Ministry of Agriculture; 1926: 747
• 3 Cruz G. Dicionário das plantas úteis do Brasil [Dictionary of useful plants from Brazil]. Rio de Janeiro: Civilização Brasileira S. A.; 1979: 599
• 4 Almeida SP, Silva JA, Ribeiro JF. Aproveitamento alimentar de espécies nativas dos cerrados: araticum, barú, cagaita e jatobá [Food utilization of native species from Cerrado: araticum, barú, cagaitaand jatobá]. 1st ed.. Planaltina: EMBRAPA; 1987: 83
• 5 Lorenzi H, Matos FJA. Plantas medicinais brasileiras: Nativas e exóticas cultivadas [Brazilian medicinal plants: native and exotic cultivated]. Nova Odessa: Plantarum Institute; 2002
• 6 De Mesquita ML, Grellier P, Mambu L, Paula JE, Espindola LS. In vitro antiplasmodial activity of Brazilian Cerrado plants used as traditional remedies. J Ethnopharmacol 2007; 110: 165-170
• 7 Vilar JB, Ferreira FL, Ferri PH, Guillo LA, Chen CL. Assessment of the mutagenic, antimutagenic and cytotoxic activities of ethanolic extract of araticum (Annona crassiflora Mart. 1841) by micronucleus test in mice. Braz J Biol 2008; 68: 141-147
• 8 Vilar JB, Ferri PH, Chen-Chen L. Genotoxicity investigation of araticum (Annona crassiflora Mart., 1841, Annonaceae) using SOS-Inductest and Ames test. Braz J Biol 2011; 71: 197-202
• 9 Lage GA, Medeiros FD, Furtado WD, Takahashi JA, de Souza JD, Pimenta LPS. The first report on flavonoid isolation from Annona crassiflora Mart. Nat Prod Res 2014; 28: 808-811
• 10 Filho AW, Filho VC, Olinger L, de Souza MM. Quercetin: further investigation of its antinociceptive properties and mechanisms of action. Arch Pharm Res 2008; 31: 713-721
• 11 Kaur R, Singh D, Chopra K. Participation of alpha (2) receptors in the antinociceptive activity of quercetin. J Med Food 2005; 8: 529-532
• 12 Naidu PS, Singh A, Kulkarni SK. D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin. Indian J Exp Biol 2003; 41: 1400-1404
• 13 Shrinivasan M, Skariyachan S, Aparna V, Kolte VR. Homology modelling of CB1 receptor and selection of potential inhibitor against obesity. Bioinformation 2012; 8: 523-528
• 14 Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioural, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173-190
• 15 Walpole MA. Massachusetts Pain Initiative: Pain survey executive summary. Available at. http://masspaininitiative.org/files/MassPI_Pain_Survey_-_Executive_Summary_v3.pdf Accessed February 18, 2016
• 16 Governdale L. Outpatient prescription opioid utilization in the US, years 2000 – 2009. Department of Epidemiology, Office of Surveillance and Epidemiology. Silver Spring, MD: US Food and Drug Administration; 2010
• 17 Braden JB, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD. Trends in use of opioids by noncancer pain type 2000–2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain 2008; 9: 1026-1035
• 18 Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004; 109: 514-519
• 19 Sullivan MD, Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138: 440-449
• 20 Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9: 444-459
• 21 Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 2005; 168: 509-554
• 22 Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462
• 23 Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-649
• 24 Anjaneyulu M, Chopra K. Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1001-1005
• 25 Valério DA, Georgetti SR, Magro DA, Casagrande R, Cunha TM, Vicentini FT, Vieira SM, Fonseca MJV, Ferreira SH, Cunha FQ, Verri WA. Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production. J Nat Prod 2009; 72: 1975-1979
• 26 Martínez AL, González-Trujano ME, Aguirre-Hernández E, Moreno J, Soto-Hernández M, López-Muñoz FJ. Antinociceptive activity of Tiliaamericana var. mexicana inflorescences and quercetin in the formalin test and in an arthritic pain model in rats. Neuropharmacology 2009; 56: 564-571
• 27 Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004; 24: 851-874
• 28 Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploration. Nat Rev Drug Discov 2004; 3: 771-784
• 29 Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65
• 30 Romero TRL, Pacheco DFP, Duarte IDG. Probable involvement of Ca²⁺-activated Cl⁻ channels (CaCCs) in the activation of CB₁ cannabinoid receptors. Life Sci 2013; 92: 815-820
• 31 Romero TR, Resende LC, Guzzo LS, Duarte IDG. CB₁ and CB₂ cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 2013; 116: 463-472
• 32 Sañudo-Peña MC, Strangman NM, Mackie K, Walker JM, Tsou K. CB₁ receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacol Sin 1999; 20: 1115-1120
• 33 Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP, Anand P. Cannabinoid receptor CB₂ localization an agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008; 138: 667-680
• 34 Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 2000; 11: 1231-1235
• 35 Ortega-Gutiérrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005; 52: 163-168
• 36 Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009; 11: 39-44
• 37 Pacheco DF, Klein A, Perez AC, Pacheco CMF, Francischi JN, Duarte IDG. The µ-opioid receptor agonist morphine, but not agonists at δ- or κ-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 2008; 154: 1143-1149
• 38 Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, Lichtman AH. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 2013; 92: 498-505
• 39 Galdino G, Romero TR, Silva JF, Aquiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F, Duarte ID, Di Marzo V, Perez AC. The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology 2014; 77: 313-324
• 40 Green AF, Young PA. A comparison of heat and pressure analgesiometric methods in rats. Br J Pharmacol Chemother 1951; 6: 572-585
• 41 Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409-419